LR 09
Relapsed leukemia post allogeneic stem cell transplantation
Not DisclosedActive
Key Facts
Indication
Relapsed leukemia post allogeneic stem cell transplantation
Phase
Not Disclosed
Status
Active
Company
About Laevoroc Oncology
Laevoroc Oncology is a private, pre-revenue biotech developing a diversified oncology portfolio through a unique subsidiary structure. Its pipeline includes LR 09, a PNP inhibitor for post-transplant leukemia relapse, and LR 06, an oral gemcitabine prodrug for maintenance therapy, developed via a joint venture. The company's strategy focuses on creating resilient, independently financed assets with high potential in areas of significant unmet need, such as hematological cancers and chemotherapy reformulation.
View full company profile